Methods of treating mitochondrial disorders
US-2020206361-A1 · Jul 2, 2020 · US
US11624685B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11624685-B2 |
| Application number | US-201916660348-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 22, 2019 |
| Priority date | May 25, 2016 |
| Publication date | Apr 11, 2023 |
| Grant date | Apr 11, 2023 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present disclosure provides methods of preparing a biological specimen for imaging analysis, comprising fixing and clearing the biological specimen and subsequently analyzing the cleared biological specimen using microscopy. Also included are methods of quantifying cells, for example, active populations of cells in response to a stimulant. The present disclosure also provides devices for practicing the described methods. A flow-assisted clearing device provides rapid clearing of hydrogel-embedded biological specimens without the need of specialized equipment such as electrophoresis or perfusion devices.
Opening claim text (preview).
What is claimed is: 1. A method for quantifying an active neuronal population of a subject animal exposed to a stimulant, the method comprising: i) delivering a stimulant to the subject animal; ii) isolating the brain of the subject animal; iii) preparing the brain of the animal to produce a cleared brain by: a) fixing the brain with a plurality of hydrogel monomers to produce a hydrogel-fixed brain; b) clearing the hydrogel-fixed brain using a non-electrophoretic flow-assisted clearing device to produce a cleared brain, wherein the clearing is performed by immersing the hydrogel-fixed brain in a buffer in a sample chamber of the flow-assisted clearing device and flowing the buffer through the hydrogel-fixed brain by using a buffer circulator, wherein the buffer flow through the hydrogel-fixed brain is unidirectional; and c) contacting the cleared brain with a refractive index matching solution; iv) imaging the cleared brain; and v) identifying the active neuronal population. 2. The method of claim 1 , further comprising incubating the cleared brain in a mounting medium prior to imaging. 3. The method of claim 2 , wherein the mounting medium is RapidClear Mounting Gel. 4. The method of claim 1 , wherein the active neuronal population of the animal is labeled. 5. The method of claim 4 , wherein the active neuronal population of the animal is labeled by targeted recombination in active populations (TRAP). 6. The method of claim 1 , further comprising administering a tamoxifen to the animal to induce targeted recombination in active populations. 7. The method of claim 6 , wherein the tamoxifen is 4-hydroxytamoxifen. 8. The method of claim 1 , wherein the step of identifying the active neuronal population comprises: i) illuminating the cleared brain with two light sheets from a first side and a second side to produce a sample image volume, wherein the second side is opposite to the first side; ii) registering the sample image volume to a reference image volume to produce a registered sample image volume; and iii) identifying the active neuronal population from the registered sample image volume. 9. The method of claim 8 , wherein the sample image volume is deconvolved. 10. The method of claim 8 , wherein the registering comprises nonlinearly registering the sample image volume to the reference image volume to produce a nonlinear registration. 11. The method of claim 10 , wherein identifying the active neuronal population further comprises: i) identifying an active cell location in the sample image volume; and ii) mapping the active cell location to the registered sample image volume. 12. The method of claim 11 , wherein the mapping further comprises: i) generating a binary mask volume for a specified region in the nonlinear registration; and ii) counting numbers of active cells in the active cell location. 13. The method of claim 12 , wherein the specified region is manually specified. 14. The method of claim 12 , wherein the specified region comprises a pre-specified region from an Allen Brain Atlas image volume. 15. The method of claim 8 , wherein the reference image volume is generated by: i) globally aligning a plurality of image volumes obtained from a plurality of cleared brains to an Allen Brain Atlas image volume; and ii) averaging the plurality of globally aligned image volumes. 16. The method of claim 15 , wherein the globally aligning comprises affine registration and/or spline registration. 17. The method of claim 15 , wherein the Allen Brain Atlas image volume is an Allen Brain Atlas Nissl-stained image volume. 18. The method of claim 1 , wherein the stimulant is amphetamine, caffeine, ephedrine, 3,4-methylenedioxymethamphetamine (MDMA), methylenedioxypyrovalerone (MDPV), prolintane, mephedrone, methamphetamine, nicotine, phenylpropanolamine, propylhexedrine, dimethylamylamine, pseudoephedrine, cathinone, or cocaine. 19. The method of claim 1 , wherein the stimulant generates a rewarding or aversive experience in the subject animal. 20. The method of claim 1 , wherein the stimulant is a physical stimulant.
Specific component of sample, medium or buffer · CPC title
comprising a directional router, e.g. directional coupler, circulator · CPC title
the pump being a peristaltic pump · CPC title
the pump being a membrane pump · CPC title
of the peristaltic pump type (peristaltic pumps per se F04B43/12) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.